Spinning off Small Companies
This article was originally published in Start Up
Executive Summary
The post-merger cutting room floor creates a great source of new companies and products--it’s good asset management for Big Pharma, and it’s good for medical entrepreneurs. But culturally and structurally, most large companies just can’t go along with the business logic of spin-offs. Technology that does get spun off is most often completely peripheral to the parent’s business--e.g., in vitro diagnostic applications or software and equipment systems from a drug company.
You may also be interested in...
The Resurrection of Affymax
A group of venture firms decided to buy Affymax from GSK at a bargain-basement valuation. They felt it had not merely the makings of a product company but could jumpstart the creation of a fully integrated biology/screening/chemistry drug discovery company. In effect, they bought, at a discount, a proto-Vertex that wouldn't have to wait nearly a decade to see a valuation explosion.
Schering Lets Metagen Flex Its Muscles
By spinning off 50% of Metagen, Schering gets an opportunity to concentrate on near-term projects, leaving Metagen free to seek funding for its early stage research from other partners
Commercializing Rare Disease Therapies Is Getting Tougher
For an industry increasingly dominated by these drugs, commercial programs need to take on the risk once reserved for development.